The Asia Pacific In Vitro Toxicity Testing Market is expected to witness market growth of 11.6% CAGR during the forecast period (2022-2028).
The availability of various tools in the biotechnology and bioinformatics divisions for conducting in-silico simulations on animal models is also a factor in industry influence. In addition, the growth of toxicology databases for the in-silico study of various chemicals is expected to drive demand for in-vitro procedures, resulting in industry advancement.
Market stability is projected to be enhanced by significant government research funding combined with clear reimbursement rules to build automated and technically sophisticated lab tests and ex-vivo studies equipment.
To uncover the essential routes and elements of these regulatory mechanisms in the reactions to toxin exposure, in vitro toxicity testing should be based on a thorough knowledge of the physiological processes associated with toxicological endpoints. Based on previous carcinogenicity research, the number of significant pathways is predicted to be in the tens to hundreds.
PMDA is responsible for the management of medicines and medical equipment in Japan. PMDA undertakes scientific assessments of marketing permission applications for pharmaceuticals in collaboration with the Ministry of Health, Labour, and Welfare's Pharmaceutical and Food Safety Bureau to monitor their post-market safety. To set testing standards for medical equipment, the International Organization for Standardization (ISO) rules are employed (FDA, 2016b). The GPMT, Buehler testing and LLNA are all accepted methods for medical device skin sensitization testing. However, comparable non-animal tests for pharmaceuticals and medical devices have yet to be accepted by the PMDA.
The South Korean Pharmaceutical Affairs Act covers a wide range of issues concerning pharmaceuticals in South Korea. Risk and ef?ciency assessments for pharmaceuticals intended for human use are handled by the National Institute of Food and Drug Safety Evaluation, which is part of the Ministry of Food and Drug Safety in South Korea. Remedies, herbal medicines, quasi-drugs, and biological materials applied directly to the skin or mucosae have all been tested for sensitization potential.
The China market dominated the Asia Pacific In Vitro Toxicity Testing Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $2,771.8 Million by 2028. The Japan market is anticipated to grow at a CAGR of 11% during (2022-2028). Additionally, The India market is expected to exhibit a CAGR of 12.3% during (2022-2028).
Based on Type, the market is segmented into Absorption, Toxic Substances, and Dose. Based on Technology, the market is segmented into Cell Culture Technologies, High Throughput Technologies, and Toxicogenomics. Based on End User, the market is segmented into Cosmetics & Households Products, Pharmaceuticals Industry, Food Industry, Chemicals, and Industry. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., General Electric (GE) Co., AstraZeneca PLC, Catalent, Inc., Laboratory Corporation of America Holdings, Acacia Pharma Group Plc, GlaxoSmithKline PLC, Helsinn Healthcare SA., and Heron Therapeutics, Inc.
By Type
By Country
The availability of various tools in the biotechnology and bioinformatics divisions for conducting in-silico simulations on animal models is also a factor in industry influence. In addition, the growth of toxicology databases for the in-silico study of various chemicals is expected to drive demand for in-vitro procedures, resulting in industry advancement.
Market stability is projected to be enhanced by significant government research funding combined with clear reimbursement rules to build automated and technically sophisticated lab tests and ex-vivo studies equipment.
To uncover the essential routes and elements of these regulatory mechanisms in the reactions to toxin exposure, in vitro toxicity testing should be based on a thorough knowledge of the physiological processes associated with toxicological endpoints. Based on previous carcinogenicity research, the number of significant pathways is predicted to be in the tens to hundreds.
PMDA is responsible for the management of medicines and medical equipment in Japan. PMDA undertakes scientific assessments of marketing permission applications for pharmaceuticals in collaboration with the Ministry of Health, Labour, and Welfare's Pharmaceutical and Food Safety Bureau to monitor their post-market safety. To set testing standards for medical equipment, the International Organization for Standardization (ISO) rules are employed (FDA, 2016b). The GPMT, Buehler testing and LLNA are all accepted methods for medical device skin sensitization testing. However, comparable non-animal tests for pharmaceuticals and medical devices have yet to be accepted by the PMDA.
The South Korean Pharmaceutical Affairs Act covers a wide range of issues concerning pharmaceuticals in South Korea. Risk and ef?ciency assessments for pharmaceuticals intended for human use are handled by the National Institute of Food and Drug Safety Evaluation, which is part of the Ministry of Food and Drug Safety in South Korea. Remedies, herbal medicines, quasi-drugs, and biological materials applied directly to the skin or mucosae have all been tested for sensitization potential.
The China market dominated the Asia Pacific In Vitro Toxicity Testing Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $2,771.8 Million by 2028. The Japan market is anticipated to grow at a CAGR of 11% during (2022-2028). Additionally, The India market is expected to exhibit a CAGR of 12.3% during (2022-2028).
Based on Type, the market is segmented into Absorption, Toxic Substances, and Dose. Based on Technology, the market is segmented into Cell Culture Technologies, High Throughput Technologies, and Toxicogenomics. Based on End User, the market is segmented into Cosmetics & Households Products, Pharmaceuticals Industry, Food Industry, Chemicals, and Industry. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., General Electric (GE) Co., AstraZeneca PLC, Catalent, Inc., Laboratory Corporation of America Holdings, Acacia Pharma Group Plc, GlaxoSmithKline PLC, Helsinn Healthcare SA., and Heron Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Absorption
- Toxic Substances
- Dose
- Cell Culture Technologies
- High Throughput Technologies
- Toxicogenomics
- Cosmetics & Households Products
- Pharmaceuticals Industry
- Food Industry
- Chemicals Industry
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc.
- General Electric (GE) Co.
- AstraZeneca PLC
- Catalent, Inc.
- Laboratory Corporation of America Holdings
- Acacia Pharma Group Plc
- GlaxoSmithKline PLC
- Helsinn Healthcare SA.
- Heron Therapeutics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific In Vitro Toxicity Testing Market by Type
Chapter 4. Asia Pacific In Vitro Toxicity Testing Market by Technology
Chapter 5. Asia Pacific In Vitro Toxicity Testing Market by End User
Chapter 6. Asia Pacific In Vitro Toxicity Testing Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- General Electric (GE) Co.
- AstraZeneca PLC
- Catalent, Inc.
- Laboratory Corporation of America Holdings
- Acacia Pharma Group Plc
- GlaxoSmithKline PLC
- Helsinn Healthcare SA.
- Heron Therapeutics, Inc.
Methodology
LOADING...
